Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2021 07:30 ET | Source: Biogen Inc.

Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data

TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current...
May 10, 2021 16:06 ET | Source: Biogen Inc.

Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

Collaboration aims to identify novel AAV capsids with enhanced properties to facilitate the development of new gene therapies for CNS and neuromuscular disordersCapsigen’s screening technology is...
April 28, 2021 18:20 ET | Source: Biogen Inc.

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...
April 28, 2021 07:30 ET | Source: Biogen Inc.

Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics

Accelerated action on climate, health and equity, including new plastic-free packaging goals for finished goods by 20251Disclosed 2020 global pay equity analysis results2 and launched enhanced...
April 19, 2021 07:30 ET | Source: Biogen Inc.

Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Initial findings from the DEVOTE study suggest no new safety concerns and support continued development of a higher dose of SPINRAZA® (nusinersen)Additional research reinforces the potential of...
April 16, 2021 07:30 ET | Source: Biogen Inc.

New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

New findings from MS PATHS show that treatment with TYSABRI® (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus® (ocrelizumab)Real-world data from...
April 15, 2021 16:30 ET | Source: Biogen Inc.

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needsMore than 500,000 individuals worldwide living with...
April 14, 2021 16:06 ET | Source: Biogen Inc.

Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021

CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer’s disease...
April 09, 2021 16:30 ET | Source: Biogen Inc.

Biogen Announces Two New Nominees for Election to Board of Directors

Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscienceCompany thanks Director Robert W. Pangia as he retires from the Board ...
April 08, 2021 07:00 ET | Source: Biogen Inc.

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA® (tocilizumab)Biosimilars have the potential...